image credit: Adobe Stock

Ferring, with manufacturing update, takes a step towards first gene therapy sales

June 13, 2023

Ferring’s Adstiladrin had been in development since 2011 and, with last year’s approval, is now on track for initial marketing.

The gene therapy treats a high-risk form of the most common type of bladder cancer, known as non-muscle invasive bladder cancer, or NIMBC, that is unresponsive to Bacillus Calmette-Guérin therapy. It uses an adenovirus vector to deliver a gene for the immune-stimulating protein interferon alfa-2b, administered once every three months via a catheter to the bladder.

But common to gene therapies are manufacturing hurdles and viral vector bottlenecks, even after the challenging development process.

Read More on Biopharma Dive